Merck’s Pimicotinib Sustains Tumor Response Over Two Years in Phase 3 TGCT Trial

• Merck reported sustained tumor control and symptom improvements over two years in its Phase 3 MANEUVER trial of pimicotinib for tenosynovial giant cell tumor.
• Joint function benefits persisted through two years; the safety profile remained consistent with earlier analyses.
• The results are being presented today at the European Society for Medical Oncology Congress 2026.
• Pimicotinib received clearance in China in December 2025 and Canada in June 2026; its U.S. application remains under FDA review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief via Business Wire (Ref. ID: 202610260700BIZWIRE_USPR_____20261022_BW078233) on October 26, 2026, and is solely responsible for the information contained therein.